Feature

Public biotech in 2016—the numbers

The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.

  • Subscribe to Nature Biotechnology for full access:

    $250

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Billion-dollar deals end eras of Ariad and Actelion. Nat. Biotechnol. 35, 183–184 (2017).

  2. 2.

    Biotech's wellspring-a survey of the health of the private sector in 2016. Nat. Biotechnol. 35, 413–420 (2017).

  3. 3.

    Fresh from the biotech pipeline—2016. Nat. Biotechnol. 35, 108–112 (2017).

  4. 4.

    et al. US immigration order strikes against biotech. Nat. Biotechnol. 35, 204–206 (2017).

  5. 5.

    Alnylam terminates revusiran program, stock plunges. Nat. Biotechnol. 34, 1213–1214 (2016).

  6. 6.

    America's drug problem. Nat. Biotechnol. 34, 1231–1241 (2017).

Download references

Author information

Affiliations

  1. Chris Morrison is a freelance writer based in Yardley, Pennsylvania, USA, and

    • Chris Morrison
  2. Riku Lähteenmäki is a freelance writer working in Turku, Finland.

    • Riku Lähteenmäki

Authors

  1. Search for Chris Morrison in:

  2. Search for Riku Lähteenmäki in:

Supplementary information

Excel files

  1. 1.

    Supplementary Text and Figures

    Supplementary Table 1